Cardinal Health (NYSE:CAH) Updates FY 2026 Earnings Guidance

Cardinal Health (NYSE:CAH) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 10.700-10.80 for the period, compared to the consensus earnings per share estimate of 10.320. The company issued revenue guidance of -.

Cardinal Health Stock Performance

Shares of NYSE CAH opened at $195.13 on Friday. The stock has a market cap of $45.92 billion, a P/E ratio of 28.08, a P/E/G ratio of 1.19 and a beta of 0.53. The firm has a 50 day moving average price of $213.73 and a 200 day moving average price of $205.46. Cardinal Health has a 52-week low of $137.75 and a 52-week high of $233.60.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings data on Thursday, April 30th. The company reported $3.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.38. The firm had revenue of $60.94 billion during the quarter, compared to analysts’ expectations of $62.10 billion. Cardinal Health had a net margin of 0.62% and a negative return on equity of 92.61%. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.35 earnings per share. Cardinal Health has set its FY 2026 guidance at 10.700-10.80 EPS. Analysts predict that Cardinal Health will post 10.79 earnings per share for the current fiscal year.

Cardinal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Wednesday, April 1st were issued a dividend of $0.5107 per share. The ex-dividend date was Wednesday, April 1st. This represents a $2.04 dividend on an annualized basis and a yield of 1.0%. Cardinal Health’s payout ratio is currently 29.35%.

Analysts Set New Price Targets

CAH has been the subject of a number of analyst reports. TD Cowen boosted their price objective on shares of Cardinal Health from $251.00 to $255.00 and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. boosted their price objective on shares of Cardinal Health from $209.00 to $243.00 and gave the company a “neutral” rating in a report on Tuesday, February 10th. Barclays boosted their price objective on shares of Cardinal Health from $243.00 to $258.00 and gave the company an “overweight” rating in a report on Tuesday, February 24th. Robert W. Baird set a $248.00 price target on shares of Cardinal Health in a report on Friday. Finally, Morgan Stanley upped their price target on shares of Cardinal Health from $245.00 to $255.00 and gave the company an “overweight” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $243.67.

Cardinal Health News Roundup

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q3 non?GAAP earnings beat estimates and company raised FY?2026 guidance to $10.70–$10.80, above consensus — the core bullish catalyst. PR Newswire: Q3 Results & Outlook
• Positive Sentiment: Company executed $250M additional share repurchase (bringing FY26 repurchases to $1.0B) and reduced debt — shareholder?friendly actions that support the share price. PR Newswire: Buybacks & Debt Reduction
• Neutral Sentiment: Wells Fargo cut its price target from $256 to $245 but kept an “overweight” rating, signaling continued analyst confidence despite the trim. Benzinga: Wells Fargo PT Change
• Neutral Sentiment: Full earnings call and transcripts are available for investors who want details on segment performance and management commentary. Yahoo Finance: Earnings Transcript Seeking Alpha: Call Transcript
• Negative Sentiment: Revenue missed expectations ($60.9B reported vs. ~$62.1B est.), which prompted media coverage and short?term selling pressure despite the EPS beat. Benzinga: Revenue Miss Coverage
• Negative Sentiment: GAAP results were weaker: GAAP operating earnings and GAAP EPS declined, driven in part by a $184M pre?tax goodwill impairment in the Navista & ION reporting unit — a one?time charge that reduces headline profitability. PR Newswire: Goodwill Impairment
• Negative Sentiment: Several outlets highlighted the “mixed” nature of the report (EPS/guidance vs. revenue/GAAP weakness), which can increase volatility and keep some investors on the sidelines. CNBC: Mixed Results Coverage

Institutional Trading of Cardinal Health

A number of institutional investors have recently made changes to their positions in CAH. Integrated Wealth Concepts LLC lifted its position in shares of Cardinal Health by 6.9% in the first quarter. Integrated Wealth Concepts LLC now owns 4,363 shares of the company’s stock worth $601,000 after purchasing an additional 280 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Cardinal Health by 198.3% in the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company’s stock worth $27,000 after purchasing an additional 14,034 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Cardinal Health in the second quarter worth $1,935,000. Cerity Partners LLC raised its position in Cardinal Health by 17.0% during the second quarter. Cerity Partners LLC now owns 40,426 shares of the company’s stock worth $6,792,000 after acquiring an additional 5,880 shares in the last quarter. Finally, Nebula Research & Development LLC raised its position in Cardinal Health by 34.4% during the second quarter. Nebula Research & Development LLC now owns 10,334 shares of the company’s stock worth $1,736,000 after acquiring an additional 2,646 shares in the last quarter. Institutional investors own 87.17% of the company’s stock.

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.